DBV Technologies (Nasdaq: DBVT) has agreed to sell approximately $50 million of American Depositary Shares (ADSs) under its At-The-Market (ATM) program on Nasdaq to RA Capital Management, through Citizens JMP Securities as sales agent. Each ADS represents five new ordinary shares.The company will issue 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS, equivalent to €2.3824 per ordinary share, a 0.15% discount to the last Euronext Paris closing price of €2.39. Settlement and delivery are expected on August 3, 2026.The new shares will represent 6.18% of existing Euronext Paris-listed shares and imply approximately 5.82% dilution for current shareholders. Post‑transaction, total shares increase from 296,087,162 to 314,375,382, with RA Capital holding 18,288,220 shares (5.82% of capital).

DBV Technologies (Nasdaq: DBVT, Euronext: DBV) has filed an automatically effective shelf registration statement on Form S-3ASR with the SEC, including a base prospectus and a sales agreement prospectus supplement, to refresh its existing at-the-market offering program for up to $150 million of American Depositary Shares (ADSs).The ATM program, conducted under a September 5, 2025 sales agreement with Citizens JMP Securities acting as sales agent, keeps total capacity at $150 million by carrying forward previously registered but unsold ADSs and adding newly registered capacity. Each ADS represents five ordinary shares, and issuances are subject to French regulatory limits, including a Prospective Regulation exemption for offerings to qualified investors representing less than 30% of securities already admitted over 12 months. DBV intends to use any net proceeds mainly for manufacturing expansion, BLA activities in ages 1–3 and 4–7, potential launch preparation of Viaskin Peanut in ages 4–7 if approved, product development, and general corporate purposes.

Covering the semester ended June 30, 2026, the filing is available in French to consult or download via the company and AMF websites.

DBV Technologies (Nasdaq: DBVT) reported second quarter and half-year 2026 results, highlighting continued regulatory progress for the VIASKIN® Peanut Patch in children aged 4–7 years. The company is engaged in detailed, ongoing interactions with the FDA and now anticipates submitting its BLA in the third quarter of 2026, with no additional data requested to date.DBV closed enrollment in the COMFORT Toddlers safety study, initiated the THRIVE study in infants, and remains funded into the third quarter of 2027, supported by $174.9 million in cash and cash equivalents at June 30, 2026. For the first half of 2026, operating income was $1.6 million, operating expenses $100.1 million, and net loss $98.0 million, or $(0.23) per share, compared with a $(0.58) loss per share a year earlier. Net cash used in operating and investing activities rose to $102.6 million, reflecting increased clinical, manufacturing, and commercial readiness investments.

Index inclusion took effect June 22 for the clinical-stage biotech. Euronext's Tech Leaders group spans 100+ companies across European markets.

DBV Technologies (Nasdaq: DBVT), a late-stage biopharmaceutical company, will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, FL.CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruption.

DBV Technologies (Nasdaq: DBVT) held its 2026 Combined General Meeting in Châtillon, France, on June 3, 2026. The meeting was chaired by Michel de Rosen, Chairman of the Board of Directors.Shareholders approved all resolutions submitted by the Board. Detailed resolutions and voting results are available on the company’s website.

DBV Technologies (Nasdaq: DBVT) reported the first participant screened in THRIVE, a Phase 2, single-arm, open-label study of the VIASKIN Peanut Patch in infants 6–12 months with peanut allergy.Infants receive daily patch treatment for 36 months, followed by a 12‑month period assessing ad lib peanut consumption.

DBV Technologies (NASDAQ:DBVT) reported Q1 2026 results with $229M cash as of March 31, 2026, funding operations into Q2 2027 after full exercise of PIPE warrants.Q1 results show net loss $47.6M and increased R&D and SG&A spending as the company advances BLA submissions for VIASKIN® Peanut Patch and commercial readiness in the U.S.

DBV Technologies (NASDAQ:DBVT) will be releasing its Q4 2025 earnings before the market opens on Friday, April 10. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-10-dbv-technologies-sa-stock/)

DBV Technologies (Nasdaq: DBVT) announced it filed its 2025 Annual Report on Form 10-K with the SEC and its 2025 Universal Registration Document (2025 URD) with the AMF on March 26, 2026.The 2025 URD includes the annual financial report, the Board of Directors' corporate governance report under Article L.225-37, the description of the share buy-back program, statutory auditor reports, and auditor fees. Documents are available on the company website, the SEC site, and the AMF site.

DBV Technologies (Nasdaq: DBVT) reported full year 2025 results and a business update focused on advancing VIASKIN® Peanut Patch clinical programs for ages 1–7 and preparing for BLA submissions.Key facts: positive Phase 3 VITESSE topline, 2025 PIPE and ATM financings, $194.2M cash at 12/31/2025 plus $94M received January 2026, and cash runway into Q2 2027.

DBV Technologies (Euronext: DBV; Nasdaq: DBVT) will join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The Scientific Council admitted DBV on March 12, 2026, and the index changes took effect on March 23, 2026.The company said inclusion should boost visibility with French and European investors as it advances toward commercialization and continued development in food allergy therapies.

YouTube video by Le Média 24-7

DBV Technologies reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety.

Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in

YouTube video by BirGün TV

YouTube video by HOLAQUETAL?

DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.